Analysis Boosts Fluvoxamine for COVID, But What’s the Evidence?
There’s a strong likelihood that the antidepressant fluvoxamine (Luvox) may moderately lower rates of hospitalization due to COVID-19 in unvaccinated patients, a new systematic review and meta-analysis has found. But outside experts differ over whether the evidence from just three studies is strong enough to warrant adding the drug to the COVID-19 armamentarium. The report, […]
COVID-19 Study Updates